Tuberculosis is consistently in the top three communicable pathogens globally. In 2021, MPP signed a licence agreement with Tandem Nano Ltd., the University of Liverpool start-up focused on the development of its proprietary long-acting nanosystems [LG1] platform technology. There is much excitement in the tuberculosis treatment community about the potential of this long-acting medicine, with several members […]
04 December 2025
Keyword